717Tip an Open-Label, Multicentre, Dose-Escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 (dual Arginase 1 and Arginase 2 Inhibitor) in Patients with Selected Advanced And/or Metastatic Solid Tumors